Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib
Journal of Investigative Dermatology · 2026-09 · 146 (9) · 2465-2474.e7
DOI: 10.1016/j.jid.2026.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026-09. Verfasst von Wenjing Jiang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Basophils, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Project, National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Program key projects.
Abstract (Originalsprache)
Basophils are increasingly recognized as key contributors to the pathogenesis of atopic dermatitis (AD), yet how targeted therapies modulate their phenotype and function remains poorly defined. We investigated the effects of dupilumab and abrocitinib on basophil activation in AD using flow cytometry, ex vivo stimulation assays, and immunofluorescence analysis. Compared with healthy controls, patients with AD showed elevated circulating basophil counts and increased expression of FcεRIα, MRGPRX2, and CD63. MRGPRX2-expressing basophils were also detected in lesional AD skin and exhibited further upregulation upon ex vivo stimulation. Both dupilumab and abrocitinib improved clinical symptoms, but their effects on basophils diverged. Dupilumab selectively reduced MRGPRX2 expression, whereas abrocitinib preferentially downregulated CD203c. Baseline CD63 expression on basophils correlated with clinical response to abrocitinib. Functional assays demonstrated that MRGPRX2 expression was significantly upregulated on basophils from patients with AD but not in healthy controls upon stimulation with N-formyl-Met-Leu-Phe or anti-IgE. Dupilumab selectively inhibited N-formyl-Met-Leu-Phe-induced MRGPRX2 upregulation without affecting IgE-mediated induction, whereas abrocitinib suppressed upregulation irrespective of the stimulus. These findings indicate that targeted therapies differentially modulate basophil hyperactivity, highlighting basophils as critical effector cells and MRGPRX2 as a promising biomarker for treatment response in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
- Department of Dermatology and Venereology, Hamad Medical, Doha, Qatar; Translational Research Institute, Academic Health System, Hamad Medical, Doha, Qatar; Dermatology Institute, Academic Health System, Hamad Medical,…
- Institute of Dermatology and Venereology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
- Department of Dermatology and Venereology, University of Freiburg, Germany.
- Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic ad…
Förderung
- Guangzhou Municipal Science and Technology Project
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Program key projects
- Science Fund for Distinguished Young Scholars of Guangdong Province
- Guangdong Provincial Natural Science Foundation
Zitieren
APA
Jiang, W., Xie, X., Yang, S., Xu, R., Chang, J. W., Tang, X., Yu, R., Xie, Y., Liu, W., Tang, R., Lun, L., Buddenkotte, J., Han, J., Xu, Y., Lu, P., Ji, S., Steinhoff, M., Huang, X., & Wang, F. (2026). Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib. Journal of Investigative Dermatology, 146(9), 2465-2474.e7. https://doi.org/10.1016/j.jid.2026.02.017
Vancouver
Jiang W, Xie X, Yang S, Xu R, Chang JW, Tang X, et al. Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib. Journal of Investigative Dermatology. 2026;146(9):2465-2474.e7. doi:10.1016/j.jid.2026.02.017
BibTeX
@article{Jiang2026,
author = {Jiang, Wenjing and Xie, Xinyang and Yang, Sai and Xu, Rui and Chang, Jui-Wen and Tang, Xiru and Yu, Ruixin and Xie, Yalin and Liu, Wenhui and Tang, Rui and Lun, Lerong and Buddenkotte, Joerg and Han, Jiande and Xu, Yingping and Lu, Ping and Ji, Suyun and Steinhoff, Martin and Huang, Xiaobao and Wang, Fang},
title = {Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib},
journal = {Journal of Investigative Dermatology},
year = {2026},
volume = {146},
number = {9},
pages = {2465--2474.e7},
doi = {10.1016/j.jid.2026.02.017}
}
EUVIMED